Insider Trading Activity For Audeo Oncology Inc (NASDAQ:AURX)

David Emerson Jorden , CEO of Audeo Oncology Inc (NASDAQ:AURX) reportedly Bought 247,500 shares of the company’s stock at an average price of 0.22 for a total transaction amount of $54,450.00 SEC Form

Analyst Ratings For Audeo Oncology Inc (NASDAQ:AURX)
These are No ratings tracked in the last 12 months. .
The current consensus rating for Audeo Oncology Inc (NASDAQ:AURX) is N/A (Score: NaN) with a consensus target price of N/A

Recent Trading Activity for Audeo Oncology Inc (NASDAQ:AURX)
Shares of Audeo Oncology Inc closed the previous trading session at 0.0000 with shares trading hands.